The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to ...

Vertex has secured a label expansion through the FDA's Commis | Vertex Pharmaceuticals has gained a label expansion from the ...

Leishmaniasis cases are doubling at Ohio State's hospital as sand flies expand their range, while Dr. Satoskar prepares to ...

The firm recently advanced its first candidate into clinical testing, evaluating STX-1150 as a treatment for hypercholesterolemia.

Creative Biolabs is strengthening its lipid-based delivery portfolio with enhanced lipid nanoparticle (LNP) and liposome engineering capabilities designed to support the growing demand for RNA ...

The strongest political angle is that ordinary people are being asked to absorb the cost and risk of systems they did not ...

One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.

Hiroshima University researchers have demonstrated a proof of concept for the mass production of genome-edited T cells that ...

Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...

Taxidermied, locked behind plexiglass and spinning slowly on a wooden dais in the National Museum of Scotland in Edinburgh, UK, the world’s most famous ewe remains a public spectacle three decades ...

Scribe Therapeutics’ pipeline is immature, with its lead program recently greenlit for first-in-human testing. The biotech is working on CRISPR-based therapies for cardiometabolic diseases. Scribe ...

But buzz doesn't always translate to great returns (as many who bought SpaceX shares after its post-IPO surge are finding out ...